Literature DB >> 2686548

Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits.

A Padula1, H F Chambers.   

Abstract

The efficacy of cilofungin (LY121019) for aortic valve endocarditis caused by Candida albicans in rabbits was studied. Vegetation titers were similar for cilofungin-treated and untreated rabbits. No rabbit survived beyond 5 days in either group. All rabbits given amphotericin B survived, and titers were reduced. Cilofungin was ineffective in this model.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2686548      PMCID： PMC172764          DOI： 10.1128/AAC.33.10.1822

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  A study of experimental, staphylococcal endocarditis in dogs. I. Production of the disease, its natural history, and tissue bacteriology.

Authors:  W F WALKER; M HAMBURGER
Journal:  J Lab Clin Med       Date:  1959-06

2.  Tissue penetration of amphotericin B in Candida endocarditis.

Authors:  E Rubinstein; E R Noriega; M S Simberkoff; J J Rahal
Journal:  Chest       Date:  1974-10       Impact factor: 9.410

3.  Experimental bacterial endocarditis. II. Survival of a bacteria in endocardial vegetations.

Authors:  D T Durack; P B Beeson
Journal:  Br J Exp Pathol       Date:  1972-02

4.  Studies on the mechanism of antifungal action of aculeacin A.

Authors:  H Yamaguchi; T Hiratani; K Iwata; Y Yamamoto
Journal:  J Antibiot (Tokyo)       Date:  1982-02       Impact factor: 2.649

5.  In vitro and in vivo anti-Candida activity and toxicology of LY121019.

Authors:  R S Gordee; D J Zeckner; L F Ellis; A L Thakkar; L C Howard
Journal:  J Antibiot (Tokyo)       Date:  1984-09       Impact factor: 2.649

6.  On the mode of action of a new antifungal antibiotic, aculeacin A: inhibition of cell wall synthesis in Saccharomyces cerevisiae.

Authors:  J Mizoguchi; T Saito; K Mizuno; K Hayano
Journal:  J Antibiot (Tokyo)       Date:  1977-04       Impact factor: 2.649

7.  Relationships of x-irradiation to the enhancement of Candida albicans infections.

Authors:  R S Gordee; P J Simpson
Journal:  J Bacteriol       Date:  1967-07       Impact factor: 3.490

8.  Candida albicans endocarditis: ultrastructural studies of vegetation formation.

Authors:  R A Calderone; M F Rotondo; M A Sande
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

9.  Staphylococcal endocarditis in rabbits treated with a low dose of cloxacillin.

Authors:  V Lorian; O Zak; S Kunz; J Vaxelaire
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

10.  Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species.

Authors:  E D Spitzer; S J Travis; G S Kobayashi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267
  10 in total
  10 in total

1.  Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits.

Authors:  J W Lee; P Kelly; J Lecciones; D Coleman; R Gordee; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Comparison of the efficacy of cilofungin, fluconazole and amphotericin B in the treatment of systemic Candida albicans infection in the neutropenic mouse.

Authors:  R M Bannatyne; P C Cheng; I W Fong
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

3.  Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits.

Authors:  M S Rouse; B M Tallan; J M Steckelberg; N K Henry; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species.

Authors:  A Huang; F Edwards; E M Bernard; D Armstrong; H J Schmitt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

5.  Comparison of cilofungin and amphotericin B for therapy of murine candidiasis.

Authors:  K R Smith; K M Lank; C G Cobbs; G A Cloud; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

6.  Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.

Authors:  N Khardori; H Nguyen; L C Stephens; L Kalvakuntla; B Rosenbaum; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

7.  Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis.

Authors:  D W Denning; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

8.  Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis.

Authors:  T J Walsh; J W Lee; P Kelly; J Bacher; J Lecciones; V Thomas; C Lyman; D Coleman; R Gordee; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species.

Authors:  K R Smith; K M Lank; W E Dismukes; C G Cobbs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

Review 10.  Animal models: an important tool in mycology.

Authors:  Javier Capilla; Karl V Clemons; David A Stevens
Journal:  Med Mycol       Date:  2007-12       Impact factor: 4.076
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.